Thalidomide in patients with multiple myeloma and renal failure

被引:40
作者
Fakhouri, F [1 ]
Guerraoui, H
Presne, C
Peltier, J
Delarue, R
Muret, P
Knebelmann, B
机构
[1] Hop Necker Enfants Malad, APHP, Serv Nephrol, Paris, France
[2] Hop Sud, Serv Nephrol, Amiens, France
[3] Hop Necker Enfants Malad, Hematol Serv, Paris, France
[4] Hop Jean Minjoz, Serv Pharmacol, F-25030 Besancon, France
关键词
thalidomide; multiple myeloma; pharmacokinetics; renal failure;
D O I
10.1111/j.1365-2141.2004.04875.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:96 / 97
页数:3
相关论文
共 5 条
[1]   DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION [J].
ERIKSSON, T ;
BJORKMAN, S ;
FYGE, A ;
EKBERG, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 582 (1-2) :211-216
[2]   Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia [J].
Harris, E ;
Behrens, J ;
Samson, D ;
Rahemtulla, A ;
Russell, NH ;
Byrne, JL .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) :160-161
[3]   Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma [J].
Kumar, S ;
Gertz, MA ;
Dispenzieri, A ;
Lacy, MQ ;
Geyer, SM ;
Iturria, NL ;
Fonseca, R ;
Hayman, SR ;
Lust, JA ;
Kyle, RA ;
Greipp, PR ;
Witzig, TE ;
Rajkumar, SV .
MAYO CLINIC PROCEEDINGS, 2003, 78 (01) :34-39
[4]   Review of 1027 patients with newly diagnosed multiple myeloma [J].
Kyle, RA ;
Gertz, MA ;
Witzig, TE ;
Lust, JA ;
Lacy, MQ ;
Dispenzieri, A ;
Fonseca, R ;
Rajkumar, SV ;
Offord, JR ;
Larson, DR ;
Plevak, ME ;
Therneau, TM ;
Greipp, PR .
MAYO CLINIC PROCEEDINGS, 2003, 78 (01) :21-33
[5]   Antitumor activity of thalidomide in refractory multiple myeloma. [J].
Singhal, S ;
Mehta, J ;
Desikan, R ;
Ayers, D ;
Roberson, P ;
Eddlemon, P ;
Munshi, N ;
Anaissie, E ;
Wilson, C ;
Dhodapkar, M ;
Zeldis, J ;
Barlogie, B ;
Siegel, D ;
Crowley, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571